Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution compared to standard antibodies
Nathalie Khoury,Michelle E Pizzo,Claire B Discenza,David Joy,David Tatarakis,Mihail Ivilinov Todorov,Moritz Negwer,Connie Ha,Gabrielly L De Melo,Lily Sarrafha,Matthew J Simon,Darren Chan,Roni Chau,Kylie Chew,Johann Chow,Allisa Clemens,Yaneth Robles-Colmenares,Jason C Dugas,Joseph Duque,Doris Kaltenecker,Holly Kane,Amy Leung,Edwin Lozano,Arash Moshkforoush,Elysia Roche,Thomas Sandmann,Mabel Tong,Kaitlin Xa,Yinhan Zhou,Joseph W Lewcock,Ali Ertürk,Robert G Thorne,Meredith E K Calvert,Y Joy Yu Zuchero
DOI: https://doi.org/10.1101/2024.07.11.602993
2024-07-16
Abstract:The blood-brain barrier (BBB) poses a significant challenge drug delivery to the brain. BBB-crossing molecules are emerging as a new class of therapeutics with significant potential for central nervous system (CNS) indications. In particular, transferrin receptor (TfR)- and CD98 heavy chain (CD98hc)-targeting molecules have been demonstrated to cross the BBB for enhanced brain delivery. Previously, we reported TfR and CD98hc antibody transport vehicles (ATV and ATV ) that utilize these BBB receptors to improve CNS drug delivery . Here, we provide a comprehensive and unbiased biodistribution characterization of ATV and ATV compared to a standard IgG at a multiscale level, ranging from whole-body to brain region- and cell type-targeting specificity. Mouse whole-body tissue clearing revealed distinct organ localization for each molecule. In the CNS, ATV and ATV not only achieves enhanced brain delivery but importantly, much broader parenchymal distribution in contrast to the severely limited distribution observed with a standard antibody that was not able to be improved even at very high dose levels. Using cell sorting and single-cell RNA sequencing of mouse brain, we revealed that standard IgG predominantly localizes to perivascular and leptomeningeal cells and reaches the CNS by entering the CSF, rather than crossing the BBB. In contrast, ATV and ATV enables broad parenchymal cell-specific distribution via transcytosis through brain endothelial cells (BECs) along the neurovasculature. Finally, we extended the translational relevance of our findings by revealing enhanced and broad brain and spinal cord biodistribution of ATV compared to standard IgG in cynomolgus monkey. Taken together, this multiscale analysis reveals in-depth biodistribution differences between ATV , ATV , and standard IgG. These results may better inform platform selection for specific therapeutic targets of interest, optimally matching platforms to desired CNS target engagement, peripheral organ exposures, and predict or potentially reduce off-target effects.
Neuroscience